Effectiveness and feasibility of selective intra‐arterial low dose of cisplatin infusion and concomitant radiotherapy for patients with advanced laryngeal cancer with impaired renal function: A retrospective cohort study

Abstract

AbstractBackgroundChemoradiation therapy with high‐dose cisplatin is the standard regimen against advanced squamous cell carcinoma of the larynx (SCC‐L). However, patients with renal dysfunction are ineligible for this regimen. We investigated the effectiveness and feasibility of selective intra‐arterial low‐dose cisplatin infusion and radiotherapy (modified [m]‐RADPLAT) for patients with impaired renal function.MethodsWe retrospectively reviewed the data of 77 patients with SCC‐L who received m‐RADPLAT.ResultsFourteen and 63 patients had creatinine clearance (CrCl) values of 30 ≤ CrCl < 60 mL/min and ≥60 mL/min, respectively. The m‐RADPLAT regimen led to no significant changes in serum creatinine or CrCl values post‐treatment. The 5‐year local control, overall survival, and laryngectomy‐free survival rates of the CrCl < 60 and ≥60 groups were 90.0% and 90.5%, 100% and 81.8%, and 100% and 79.0%, respectively. Grade 3 or higher toxicity rates were not significantly different between the groups.ConclusionsThe m‐RADPLAT regimen yielded favorable survival rates and clinical outcomes in patients with impaired renal function.